EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2025: EBIT below prior year – forecast confirmed due to good order development

Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2025: EBIT below prior year – forecast confirmed due to good order development

Lübeck, April 14, 2025 – In the first quarter, which is seasonally weak for Dräger, the Company generated slightly positive earnings before interest and taxes (EBIT) of around EUR 0.4 million based on preliminary calculations. However, EBIT did not reach the significantly higher prior-year figure (Q1 2024: EUR 15.1 million). This was due to the lower net sales volume and the increase in expenses compared to the same quarter of the prior year. The EBIT margin amounted to 0.1 percent (Q1 2024: 2.0 percent).

In contrast, demand for Dräger products and services developed very well in the first quarter. Order intake rose by 6.1 percent (net of currency effects; nominal 6.2 percent) to around EUR 861 million. This not only exceeded the high prior-year level (Q1 2024: EUR 810.8 million), but also reached the highest Q1 level since the record year 2020 (Q1 2020: EUR 1,392.7 million). Both divisions contributed to this positive development: after a decline in the prior year, order intake in the medical division increased by 4.2 percent (net of currency effects; nominal: 4.4 percent) to around EUR 474 million (Q1 2024: EUR 453.7 million); in the safety division, it rose by 8.4 percent (net of currency effects; nominal: 8.4 percent) to around EUR 387 million (Q1 2024: EUR 357.2 million).

At around EUR 730 million (net of currency effects: -1.2 percent; nominal: -0.8 percent), net sales almost reached the prior-year level (Q1 2024: EUR 735.8 million). The medical division recorded a decline of 1.6 percent (net of currency effects; nominal: -1.0 percent) to around EUR 413 million (Q1 2024: EUR 417.4 million). Net sales in the safety division were down 0.6 percent (net of currency effects; nominal: -0.4 percent) on the prior-year figure at around EUR 317 million (Q1 2024: EUR 318.4 million). The Group's gross profit margin rose to around 45.8 percent (Q1 2024: 45.3 percent). Functional expenses increased by 4.7 percent (net of currency effects; nominal: 5.0 percent) to around EUR 334 million (Q1 2024: EUR 317.8 million).

Forecast for 2025
For the current fiscal year, Dräger continues to expect an increase in net sales of 1.0 to 5.0 percent (net of currency effects) and an EBIT margin of 3.5 to 6.5 percent.

The potential impact of US tariff policy on our business development cannot be foreseen at present and is therefore not included in our forecast. This also includes the possible impact of exchange rate effects.

The full results for the first three months of the fiscal year will be published on April 30, 2025.

Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com

Corporate Communications:
Melanie Kamann
Tel. +49 451 882-3998
melanie.kamann@draeger.com

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company's knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company's influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.